In addition, the advantageous impact of MondoA (SBI-993), a ChREBP inhibitor analog, on muscle insulin signaling and systemic glucose tolerance has been demonstrated in the diet-induced obesity mouse model, and whether it has a therapeutic effect in MASLD remains to be further clarified (83). This evidence concerns the gene MLXIPL and metabolic dysfunction-associated steatotic liver disease.